🚀 VC round data is live in beta, check it out!
Ourofino Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ourofino and similar public comparables like Kala Bio, Sol-Gel Technologies, Acepodia, OmniAb and more.
Ourofino Overview
About Ourofino
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.
Founded
2014
HQ
Employees
1.1K
Website
Sectors
Financials (FY)
EV
$310M
Ourofino Financials
Ourofino reported last fiscal year revenue of $234M and EBITDA of $56M.
In the same fiscal year, Ourofino generated $121M in gross profit, $56M in EBITDA, and $42M in net income.
Revenue (LTM)
Ourofino P&L
In the most recent fiscal year, Ourofino reported revenue of $234M and EBITDA of $56M.
Ourofino expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $234M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $121M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 52% | XXX | XXX | XXX |
| EBITDA | — | XXX | $56M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 24% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 20% | XXX | XXX | XXX |
| Net Profit | — | XXX | $42M | XXX | XXX | XXX |
| Net Margin | — | XXX | 18% | XXX | XXX | XXX |
| Net Debt | — | — | $46M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Ourofino Stock Performance
Ourofino has current market cap of $252M, and enterprise value of $310M.
Market Cap Evolution
Ourofino's stock price is $4.68.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $310M | $252M | 1.8% | XXX | XXX | XXX | $0.79 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOurofino Valuation Multiples
Ourofino trades at 1.3x EV/Revenue multiple, and 5.6x EV/EBITDA.
EV / Revenue (LTM)
Ourofino Financial Valuation Multiples
As of March 18, 2026, Ourofino has market cap of $252M and EV of $310M.
Equity research analysts estimate Ourofino's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ourofino has a P/E ratio of 5.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $252M | XXX | $252M | XXX | XXX | XXX |
| EV (current) | $310M | XXX | $310M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 5.6x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 6.6x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.6x | XXX | XXX | XXX |
| P/E | — | XXX | 5.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 30.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ourofino Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ourofino Margins & Growth Rates
Ourofino's revenue in the last fiscal year grew by 20%.
Ourofino Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 18% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Ourofino Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Kala Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Sol-Gel Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Acepodia | XXX | XXX | XXX | XXX | XXX | XXX |
| OmniAb | XXX | XXX | XXX | XXX | XXX | XXX |
| Coherus Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ourofino M&A Activity
Ourofino acquired XXX companies to date.
Last acquisition by Ourofino was on XXXXXXXX, XXXXX. Ourofino acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ourofino
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOurofino Investment Activity
Ourofino invested in XXX companies to date.
Ourofino made its latest investment on XXXXXXXX, XXXXX. Ourofino invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ourofino
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ourofino
| When was Ourofino founded? | Ourofino was founded in 2014. |
| Where is Ourofino headquartered? | Ourofino is headquartered in Brazil. |
| How many employees does Ourofino have? | As of today, Ourofino has over 1K employees. |
| Is Ourofino publicly listed? | Yes, Ourofino is a public company listed on B3. |
| What is the stock symbol of Ourofino? | Ourofino trades under OFSA3 ticker. |
| When did Ourofino go public? | Ourofino went public in 2014. |
| Who are competitors of Ourofino? | Ourofino main competitors are Kala Bio, Sol-Gel Technologies, Acepodia, OmniAb. |
| What is the current market cap of Ourofino? | Ourofino's current market cap is $252M. |
| What is the current revenue of Ourofino? | Ourofino's last fiscal year revenue is $234M. |
| What is the current EV/Revenue multiple of Ourofino? | Current revenue multiple of Ourofino is 1.3x. |
| Is Ourofino profitable? | No, Ourofino is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.